Bioinformatic designing multi-epitope protein of muc1 against cancer

Introduction &Objectives: One of the effective treatments for cancer patients is biological treatment with epitope vaccines. In vaccine-based cancer immunotherapy, the effort is to restore the immune response to patients and to re-activate the immune system. MUC1 protein is commonly present on the surface of most secretory epithelial cells and is abnormally expressed in most human cancers. The aim of this study was to determine the specific antigenic properties of MUC1 and the bioinformatics design of a multi-epitope protein against cancer.Materials & Methods: Firstly, the Vaxquery and NCBI databases were used to determine the best vaccine candidate sequence in MUC1. Sequence conservation studies were performed by NCBI server and CLC workbench 7.5.1 software. The extracellular part of the protein was determined by the TMHMM server and for evaluating and predicting the secondary and tertiary structure of the protein Phyre2 Server was used. discontinuous and linear epitopes of B lymphocyte cells were determined by IEDB, DISCOTOPE and Ellipro servers. Predicting of MHC class I-associated T lymphocyte epitopes were evaluated on EpiJen and CTLpred servers and MHC class II lymphocyte epitopes were evaluated on ProPred and NetMHCIIpan servers. Antigenicity, toxicity and allergenicity of the peptides were determined respectively by VaxiJen, Toxinpred and Allertop servers.Results: After identifying and scoring discontinuous and linear epitopes, the sequences that were the best candidate for the vaccine were selected. standard Selection for these peptides were high protection, high immunogenicity, no toxicity and no allergenicity.Conclusion: In this study, peptids with high antigenicity were identified to be used as a preliminary design for the development of an effective cancer vaccine. Based on the early stages of bioinformatics screening of the newly designed multi-epitope protein, the designed protein is a suitable candidate for useing as a vaccine. However, further bioinformatics studies are needed to finally confirm this therapeutic vaccine designed for cancer.

کلیدواژه ها:

Multi-epitope protein ، Antigenic markers ، MUC1 ، Epitope vaccine